CVRx, Inc.
Moat Score — CVRx, Inc.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Barostim's FDA Premarket Approval, Breakthrough Device designation, and underlying baroreflex activation therapy patents give CVRx durable regulatory and IP protection as the only device of its kind on the market. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | CVRx is still working toward its 83-84% gross margin target through manufacturing scale, but as a smaller single-product company it has no structural cost advantage over larger device manufacturers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | As one of only two device-based HFrEF therapies, CVRx has some latitude in device pricing, but adoption still depends on securing adequate hospital reimbursement, which caps how aggressively it can price. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | An implantable neuromodulation device has no network effect; one patient's implant does not make the therapy more valuable to another patient. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Once a patient is implanted with Barostim and a hospital has trained physicians and built referral pathways for the therapy, there is strong continuity of care and no practical reason to switch, though this reflects implant permanence more than a true commercial lock-in mechanism. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | With only one direct device-based competitor (Cardiac Contractility Modulation) in a large but still-underpenetrated HFrEF market, CVRx benefits from limited direct competition, though this reflects category immaturity more than a defensible scale barrier. |